Alle Storys
Folgen
Keine Story von IsoTis OrthoBiologics mehr verpassen.

IsoTis OrthoBiologics

IsoTis to Release First Quarter 2007 Results on May 15

Irvine, California (ots/PRNewswire)

IsoTis, Inc (NASDAQ: ISOT),
a leading orthobiologics company, will release its first quarter 2007
results on May 15 at approximately 4:30 p.m. EST .
To discuss these results, the Company will conduct a conference
call at 5 p.m. EST / 2:00 p.m. PST/ 11:00 p.m. CET. US Dial In:
1-617-614-6206; UK Dial In +44-20-7365-8426; Continental Europe Dial
In:  +41-1-800-9569; password: ISOTIS. To listen to the conference
call live via  the internet, visit the Investors section of the
IsoTis website at www.isotis.com. Please go to the website 15 minutes
prior to the call to register, download and install the necessary
audio software.
About the company:
IsoTis is a leading orthobiologics company that develops,
manufactures and markets proprietary products for the treatment of
musculoskeletal diseases and disorders. IsoTis' current
orthobiologics products are bone graft substitutes that promote the
regeneration of bone and are used to repair natural, trauma-related
and surgically-created defects common in orthopedic procedures,
including spinal fusions. IsoTis' current commercial business is
highlighted by its Accell line of products, which the company
believes represents the next generation in bone graft substitution.

Contact:

For information contact: Rob Morocco, CFO, +1-(949)-855-7155,
robert.morocco@isotis.com; Hans Herklots, Director IR,
+1-(949)-855-7195 or +41-(21)-620-6011, hans.herklots@isotis.com

Weitere Storys: IsoTis OrthoBiologics
Weitere Storys: IsoTis OrthoBiologics
  • 03.05.2007 – 14:16

    IsoTis Receives US Patent Related to Reverse Phase Medium Technology

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced that the United States Patent and Trademark Office has awarded US Patent No. 7,205,337, which relates to the company's Reverse Phase Medium (RPM) carrier technology. The patent covers the use of IsoTis' current RPM technology in combination with various demineralized bone matrix (DBM) formulations, such as ...

  • 25.04.2007 – 14:17

    IsoTis Completes Transfer of PolyActive IP Estate to OctoPlus

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced it has completed the transfer of the rights associated with its PolyActive technology to OctoPlus (Euronext: OCTO), a drug delivery and development company, in exchange for an up-front payment of approximately $1.7 million and future royalty payments on sales of pharmaceutical products based on the ...

  • 16.04.2007 – 14:15

    /C O R R E C T I O N -- Isotis Inc/

    Irvine, California (ots/PRNewswire) - In the news release, "IsoTis Appoints James P. Abraham as Senior Vice President Sales" issued on 16 Apr 2007 12:00 GMT, by Isotis Inc nasdaq:ISOT over PR Newswire, we are advised by a representative of the company that the release is the same for several wire tasks, so the destinations will be added to this task transmitted by PR Newswire. Complete, corrected release follows: ...